Last updated: July 24, 2023
Sponsor: Induce Biologics USA Inc.
Overall Status: Active - Enrolling
Phase
N/A
Condition
N/ATreatment
Natural Matrix Protein (NMP)
Clinical Study ID
NCT05972616
SIL-2023-NMP
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Have clinical or radiological evidence of degenerative disc disease of the lumbarspine.
- Have been treated with Induce Biologics NMP™ during a lumbar spinal fusion procedure.
- Be at least 18 years of age.
- Have current contact information.
- Be willing and able to provide written Informed Consent for the prospective part ofstudy participation.
- Be willing and able to undergo a CT-scan and X-rays.
- Be willing and able to complete patient centered outcome questionnaires.
Exclusion
Exclusion Criteria:
- Currently imprisoned.
- Currently experiencing major mental illness (psychosis, schizophrenia, major affectivedisorder) which in the opinion of the investigator may indicate that the symptoms arepsychological rather than of physical origin.
- X-rays or CT-scan are contraindicated.
- Any previous lumbar fusion or arthroplasty surgery at the index level(s)
Study Design
Total Participants: 135
Treatment Group(s): 1
Primary Treatment: Natural Matrix Protein (NMP)
Phase:
Study Start date:
August 01, 2023
Estimated Completion Date:
June 30, 2024
Study Description
Connect with a study center
Spine Institute of Louisiana
Shreveport, Louisiana 71101
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.